HealthQuill non-muscle invasive bladder cancer
Anixa Biosciences, Inc., announced that its partner Cleveland Clinic has begun enrolling subjects in a treatment arm to evaluate the combination of the company's breast cancer vaccine with Merck’s Keytruda (pembrolizumab) immunotherapy.
Drugs Research

AstraZeneca’s blood cancer combination drug shows positive results in end trial

HQ Team May 13, 2025: AstraZeneca’s POTOMAC Phase III trial has demonstrated that combining Imfinzi (durvalumab) with standard Bacillus Calmette-Guérin (BCG) therapy significantly improves disease-free survival (DFS) in patients.

Read More
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received Breakthrough Therapy Designation from the USFDA.
Drugs Pharma

Moderna-Merck’s cancer vaccine gets FDA breakthrough therapy designation 

Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received.

Read More